Comment on “Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study”

IF 3.6 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Bone Pub Date : 2025-10-09 DOI:10.1016/j.bone.2025.117667

Daquan Liao , Xuezheng Zhu , Shiye Huang , Yubin Feng , Ziye Zhuang

引用次数: 0

查看原文本刊更多论文

评论“基线PINP对treatment-naïve原发性骨质疏松患者使用罗莫索单抗、特立帕肽和地诺单抗增加BMD的影响：一项回顾性队列研究”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone 医学-内分泌学与代谢

CiteScore

8.90

自引率

4.90%

发文量

264

审稿时长

30 days

期刊介绍： BONE is an interdisciplinary forum for the rapid publication of original articles and reviews on basic, translational, and clinical aspects of bone and mineral metabolism. The Journal also encourages submissions related to interactions of bone with other organ systems, including cartilage, endocrine, muscle, fat, neural, vascular, gastrointestinal, hematopoietic, and immune systems. Particular attention is placed on the application of experimental studies to clinical practice.